| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
86,568,000 |
| Market
Cap: |
1.22(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.79 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
6,611,050 |
8,088,052 |
| Total Buy Value |
$0 |
$0 |
$45,289,581 |
$53,421,765 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
9 |
| Total Shares Sold |
26,110 |
103,816 |
107,114 |
108,208 |
| Total Sell Value |
$411,056 |
$1,780,570 |
$1,802,142 |
$1,812,515 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
12 |
14 |
15 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Parlavecchio Caryn |
CHROOfficer |
• – – |
2022-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
44,300 |
|
70% |
|
| Ho Junlin |
General Counsel |
• – – |
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
75,091 |
|
- |
|
| Chyung Yung H. |
Chief Medical Officer |
• – – |
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
258,496 |
|
- |
|
| Mahanthappa Nagesh K. |
Interim CEO and President |
• – – |
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Carven Gregory John |
Chief Scientific Officer |
• – – |
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
82,708 |
|
- |
|
| Myles Edward H |
COO & CFO |
• – – |
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
57,500 |
79,472 |
|
- |
|
| Chyung Yung H. |
Chief Medical Officer |
• – – |
2022-01-18 |
4 |
D |
$19.46 |
$27,657 |
D/D |
(1,421) |
220,996 |
|
- |
|
| Ho Junlin |
General Counsel |
• – – |
2022-01-18 |
4 |
D |
$19.46 |
$20,280 |
D/D |
(1,042) |
37,591 |
|
- |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2022-01-18 |
4 |
D |
$19.46 |
$42,390 |
D/D |
(2,178) |
21,972 |
|
- |
|
| Carven Gregory John |
Chief Scientific Officer |
• – – |
2022-01-18 |
4 |
D |
$19.46 |
$22,129 |
D/D |
(1,137) |
47,708 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2021-11-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,441 |
7,441 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2021-11-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(339,098) |
0 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2021-11-17 |
4 |
A |
$0.00 |
$0 |
I/I |
56,009 |
160 |
|
- |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-11-15 |
4 |
AS |
$35.05 |
$171,006 |
D/D |
(4,879) |
24,150 |
|
-61% |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,879 |
29,029 |
|
- |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-11-12 |
4 |
AS |
$35.12 |
$1,750,437 |
D/D |
(49,848) |
24,150 |
|
-62% |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-11-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
49,848 |
73,998 |
|
- |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-11-11 |
4 |
AS |
$35.20 |
$829,857 |
D/D |
(23,574) |
24,150 |
|
-59% |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-11-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,574 |
47,724 |
|
- |
|
| Flier Jeffrey S. |
Director |
– • – |
2021-10-01 |
4 |
AS |
$30.89 |
$185,329 |
I/I |
(6,000) |
22,272 |
|
-40% |
|
| Flier Jeffrey S. |
Director |
– • – |
2021-09-20 |
4 |
S |
$34.09 |
$17,045 |
D/D |
(500) |
9,013 |
|
48% |
|
| Mahanthappa Nagesh K. |
Interim CEO and PresidentOffic |
• • – |
2021-07-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
380,491 |
|
-17% |
|
| Flier Jeffrey S. |
Director |
– • – |
2021-07-26 |
4 |
AS |
$31.48 |
$189,954 |
I/I |
(6,000) |
28,272 |
|
-21% |
|
| Ho Junlin |
General CounselOfficer |
• – – |
2021-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,633 |
|
-13% |
|
| Gilman Michael |
Director |
– • – |
2021-03-15 |
4 |
AS |
$65.59 |
$307,998 |
D/D |
(4,696) |
37,459 |
|
-52% |
|
39 Records found
|
|
Page 1 of 2 |
|
|
0.70 (4.73%) 
